Source - LSE Regulatory
RNS Number : 6125R
Tissue Regenix Group PLC
30 October 2023

Tissue Regenix Group plc

('Tissue Regenix', the 'Company' or the 'Group')


HPRA approval & distribution agreement in Spain


HPRA approval to provide an Irish logistics hub for the distribution of allograft products in the EU

New exclusive distribution agreement for Tissue Regenix's allograft products in Spain


Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that it has received approval from the Irish Health Products Regulatory Authority ('HPRA'), allowing the Company to set up a logistics hub in Ireland for the distribution of its allograft products within the European Union ('EU').


The HPRA regulates medicines and devices in Ireland for the benefit of people and animals, inspecting companies and facilities which test, make or distribute health products to ensure that they comply with relevant standards and legislation.


Tissue Regenix has also signed an exclusive distributor contract with Spineart España SLU ('Spineart') for the distribution of its allograft products in Spain. Spineart is a privately held medical device company that operates in over 60 markets, focused on simplifying surgery by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams and patients.


Daniel Lee, Chief Executive Officer of Tissue Regenix, commented: "Receiving HPRA approval is a great step for Tissue Regenix, as it will provide a logistics hub for the distribution of our allograft products to the European market. Following this, we are delighted to be partnering with Spineart to bring our allograft products to more customers in the EU. Spineart have a large global footprint that we hope in time can be leveraged to bring our products to more customers internationally."


For more information:


Tissue Regenix Group plc

David Cocke, Chief Financial Officer

via Walbrook PR

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Emily Watts/Geoff Nash/George Dollemore - Corporate Finance

Nigel Birks/Harriet Ward - ECM

Walbrook PR (Financial PR and IR)

Tel: +44 (0)20 7933 8780

Alice Woodings


About Tissue Regenix (

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.


In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Tissue Regenix Group PLC (TRX)

-0.60p (-0.97%)
delayed 11:25AM